New Analyst Forecast: $MYGN Given $12.5 Price Target
Myriad Genetics (MYGN): Buy, Sell, or Hold Post Q4 Earnings?
Analyst Sees Bottom For Myriad Genetics Stock, Issues Upgrade
Sector Update: Health Care Stocks Lower Late Afternoon
Why Are Myriad Genetics (MYGN) Shares Soaring Today
This HubSpot Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday
Myriad Genetics Raised to Overweight From Neutral by Piper Sandler
Wells Fargo Maintains Myriad Genetics(MYGN.US) With Buy Rating, Cuts Target Price to $22
Morgan Stanley Maintains Myriad Genetics(MYGN.US) With Hold Rating, Cuts Target Price to $16
Piper Sandler Upgrades Myriad Genetics(MYGN.US) to Buy Rating, Raises Target Price to $12.5
Buy Rating on Myriad Genetics: Strategic Changes and Growth Potential Amid Challenges
US$19.13: That's What Analysts Think Myriad Genetics, Inc. (NASDAQ:MYGN) Is Worth After Its Latest Results
Piper Sandler Maintains Myriad Genetics(MYGN.US) With Hold Rating, Cuts Target Price to $11.5
Analyst Expectations For Myriad Genetics's Future
Myriad Genetics Is Maintained at Underperform by B of A Securities
Express News | Myriad Genetics Inc : BofA Global Research Cuts Price Objective to $11 From $13
Myriad Genetics Faces Financial Uncertainty Amid Potential Tax Law Changes
Myriad Genetics | 10-K: FY2024 Annual Report
Myriad Genetics and Gabbi to Work Together to Increase Access to Hereditary Cancer Risk Assessment Tools
Analysts' Opinions Are Mixed on These Healthcare Stocks: Quest Diagnostics (DGX) and Myriad Genetics (MYGN)
Unlock the Full List